Overview | Agenda/Faculty Materials | Promotional Opportunities
Speaking Proposals | Administration | Contact Us | Past Events | Home




OVERVIEW

Comparative effectiveness research (CER) is a broad concept that includes different methods for synthesizing existing evidence and for generating new evidence through a variety of types of research studies. The goal is to help identify which test or treatment options work best for different kinds of patients. In addition to improving the outcomes for individual patients, this research, it is hoped, will give all health care stakeholders the means to make decisions and set policies that will ultimately shift care to higher-value options across the health care system.

Last year's federal stimulus legislation provided $1.1 billion to be distributed to the Department of Health and Human Services, the National Institutes of Health and the Agency for Healthcare Research and Quality to finance CER, including funding for studies and for the development of patient databases and other data-collecting tools. In addition, under the recently enacted Patient Protection and Affordable Care Act, a new non-profit corporation, the Patient-Centered Outcomes Research Institute (PCORI) has been established. The entity will be governed by a board consisting of the directors of AHRQ and NIH (or their designees) and 17 members appointed by the Comptroller General of the United States. It will set the national agenda for comparative effectiveness research as well as distribute funding, disseminate results, and provide annual reports to the President and Congress.

Some medical researchers, consumer groups, unions, insurance companies and others that support comparative effectiveness research say that it is one way to eliminate ineffective treatments and reduce federal health spending. Opponents of such research - which include some pharmaceutical and medical device manufacturers, medical trade groups and consumer groups - have expressed concern that the research could lead to rationed health care, inadequate treatment for some patients, such as those in minority groups, and restricted efforts at personalized medicine.

The purpose of the National Comparative Effectiveness Summit is to provide an understanding of what has changed now that comparative effectiveness is an institutionalized part of the American healthcare system. Summit presentations will draw lessons from CER experience in other countries and identify the practical implications of CER for various actors in the healthcare marketplace, including payors and health plans, hospital and health systems, physician organizations, clinicians and other healthcare professionals, and pharmaceutical, biotechnology and medical device manufacturers.

WHO SHOULD ATTEND:
  • Employers and Other Payors
  • Health Plan Representatives
  • Hospital and Health System Representatives
  • Medical Group and IPA Representatives
  • Healthcare Group Purchasing Organization Representatives
  • Healthcare Executives and Administrators
  • Clinicians and Other Healthcare Professionals
  • Healthcare Compliance Professionals and Legal Counsel
  • Pharmaceutical, Biotech and Medical Device Manufacturers
  • Disease Management and Health Promotion Companies
  • Information Technology Vendors
  • Consumer/Patient Advocates
  • Academics
  • State and Federal Regulatory Officials
  • Capitol Hill Staff
  • Administration and Congressional Representatives
  • Health Service Researchers
  • Health Policy Experts
FEATURING:

    SPECIAL SESSIONS ON:

    • Role of the Patient Centered Outcomes Research Institute (PCORI)
    • Comparative Effectiveness Research: The Legislative History and Future
    • Overview of Federal Stimulus Funding of CER
    • How States are Already Using Comparative and Cost-effective Research
    • Methods and Data Infrastructure Needed for CER
    • The Role of HIT in Comparative Effectiveness Research
    • Comparative Effectiveness versus Cost-Effectiveness
    • The Relationship between AHRQ and CMS through the Lens of CER
    • Comparative Effectiveness Research and the FDA
    • Balancing Comparative Effectiveness Research and Personalized Medicine
    • Initiatives under way to Develop Evidence of CER and put it into Practice
    • The Impact of CER on Health and Health Care Spending

    AND FEATURED TRACKS ON:

    • CER for Employers and Health Plans
    • CER for Public Programs
    • CER for Pharma and Device Manufacturers
    • CER for Healthcare Providers




Overview | Agenda/Faculty Materials | Promotional Opportunities
Speaking Proposals | Administration | Contact Us | Past Events | Home




© Health Care Conference Administrators
Contact Webmaster